scholarly journals TOP2A Gene

2020 ◽  
Author(s):  
Keyword(s):  
Top2a Gene

scholarly journals Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Jiali Meng ◽  
Yuanchao Wei ◽  
Qing Deng ◽  
Ling Li ◽  
Xiaolong Li
Keyword(s):  
Hepatocellular Carcinoma ◽  
Differential Expression ◽  
Interaction Analysis ◽  
Clinical Sample ◽  
Primary Liver Cancer ◽  
Data Set ◽  
Hub Gene ◽  
Kegg Pathways ◽  
Normal Tissues ◽  
Top2a Gene

Abstract Background Hepatocellular carcinoma (HCC) is a primary liver cancer with a high mortality rate. However, the molecular mechanism of HCC formation remains to be explored and studied. Objective To investigate the expression of TOP2A in hepatocellular carcinoma (HCC) and its prognosis. Methods The data set of hepatocellular carcinoma was downloaded from GEO database for differential gene analysis, and hub gene was identified by Cytoscape. GEPIA was used to verify the expression of HUB gene and evaluate its prognostic value. Then TOP2A was selected as the research object of this paper by combining literature and clinical sample results. Firstly, TIMER database was used to study TOP2A, and the differential expression of TOP2A gene between normal tissues and cancer tissues was analyzed, as well as the correlation between TOP2A gene expression and immune infiltration of HCC cells. Then, the expression of top2a-related antibodies was analyzed using the Human Protein Atlas database, and the differential expression of TOP2A was verified by immunohistochemistry. Then, SRTING database and Cytoscape were used to establish PPI network for TOP2A and protein–protein interaction analysis was performed. The Oncomine database and cBioPortal were used to express and identify TOP2A mutation-related analyses. The expression differences of TOP2A gene were identified by LinkedOmics, and the GO and KEGG pathways were analyzed in combination with related genes. Finally, Kaplan–Meier survival analysis was performed to analyze the clinical and prognosis of HCC patients. Results TOP2A may be a new biomarker and therapeutic target for hepatocellular carcinoma.

Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer

2013 ◽  
Vol 9 (4) ◽  
pp. 367-379 ◽  
Author(s):  
Olivera Mitrović ◽  
Vladan Čokić ◽  
Dragoslava Đikić ◽  
Mirela Budeč ◽  
Sanja Vignjević ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Molecular Subtypes ◽  
Top2a Gene ◽  
Her 2

HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas

2017 ◽  
Vol 24 (3) ◽  
pp. 575-581 ◽  
Author(s):  
Klaus Aumayr ◽  
Tobias Klatte ◽  
Barbara Neudert ◽  
Peter Birner ◽  
Shahrokh Shariat ◽  
...  
Keyword(s):  
Protein Expression ◽  
Gene Amplification ◽  
Upper Tract ◽  
Top2a Gene ◽  
Urothelial Carcinomas

Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

2012 ◽  
Vol 18 (4) ◽  
pp. 885-894 ◽  
Author(s):  
Anna Żaczek ◽  
Aleksandra Markiewicz ◽  
Anna Supernat ◽  
Natalia Bednarz-Knoll ◽  
Burkhardt Brandt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Early Breast Cancer ◽  
Prognostic Value ◽  
Chromosome 17 ◽  
Top2a Gene

scholarly journals BRCA1 and TOP2A gene amplification and protein expression in four molecular subtypes of breast cancer

2013 ◽  
Vol 65 (2) ◽  
pp. 511-518 ◽  
Author(s):  
Olivera Mitrovic ◽  
Mileva Micic ◽  
V. Cokic ◽  
Vesna Koko ◽  
Dragoslava Djikic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Significant Positive Correlation ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Protein Overexpression ◽  
Brca1 Protein ◽  
Luminal B ◽  
Top2a Gene ◽  
Top2a Amplification

We studied TOP2A amplification (using FISH methods), and TOP2A and BRCA1 protein overexpression (immunohistochemistry) in four molecular subtypes of breast cancer. Of 53 patients, 32 showed TOP2A and 38 showed BRCA1 overexpression. The highest percentage of TOP2A amplification (47.8%) and deletion (13%) was detected in Luminal B subtypes. Of 11 Luminal B tumors with TOP2A amplification, 9 (81.8%) overexpressed TOP2A. BRCA1 protein overexpression showed significant positive correlation with TOP2A protein expression. BRCA1 and TOP2A proteins exhibited similar patterns of expression in Luminal B and triple-negative breast cancer, suggesting the same prognosis in those patients.

Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline- based chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 524-524 ◽  
Author(s):  
M. F. Press ◽  
G. Sauter ◽  
M. Buyse ◽  
L. Bernstein ◽  
W. Eiermann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Topoisomerase Ii ◽  
Predictive Marker ◽  
Breast Cancers ◽  
Topoisomerase Ii Alpha ◽  
Test Set ◽  
Top2a Gene ◽  
Top2a Amplification ◽  
Her 2

524 Background: Topoisomerase II-alpha (TOP2A) gene amplification, and not HER2 amplification, may be the predictive marker for responsiveness to anthracycline chemotherapy. Methods: To address this issue we performed a test set-validation set series of analyses. Amplification of TOP2A and HER2 was evaluated by fluorescence in situ hybridization (FISH) in patients with metastatic breast cancer who participated in a randomized trial (H0648g, n = 469) of anthracycline-based chemotherapy with or without trastuzumab. This group represented the test set. To validate our observations in the H0648g test set we analyzed breast cancers from two other, large, randomized clinical studies of anthracycline-based chemotherapy; one with HER-2 amplification and trastuzumab-based therapy (BCIRG006, n = 3,222) and one without HER-2 amplification and combination-based chemotherapy (BCIRG005, n = 3,298), comparing TOP2A status with clinical outcome. Both of the latter trials were adjuvant trials. Results: In the H0648g test set patients whose breast cancers had TOP2A gene co- amplification and who were treated with doxorubicin, cyclophosphamide (AC) and trastuzumab had a longer progression-free survival compared to those who were treated with AC alone (p = 0.03). Patients treated solely with AC, whose breast cancers had TOP2A gene co-amplification had a statistically significant improvement in duration of survival compared to those without TOP2A gene amplification (p = 0.004). Among all women entered in the HER2-positive BCIRG 006 clinical trial, as well as among women who were treated with anthracycline-containing chemotherapy alone, women whose breast cancers showed TOP2A gene co-amplification had a significantly longer disease-free (p <0.001), recurrence-free (p <0.001) and overall survival (p = 0.01) compared to women whose breast cancers lacked TOP2A amplification. Unexpectedly, the added beneficial effect of trastuzumab was not seen among TOP2A co-amplified breast cancer patients in the larger BCIRG006 trial. Conclusions: In patients treated with chemotherapy alone the findings demonstrate that TOP2A gene co-amplification is a useful predictive marker of responsiveness to anthracycline-containing chemotherapy. No significant financial relationships to disclose.

Evaluation of the number of copies of the TOP2A gene and its protein expression in uterine leiomyosarcoma

2015 ◽  
Vol 137 ◽  
pp. 165-166
Author(s):  
G. Baiocchi ◽  
I.W. Cunha ◽  
F. Poliseli ◽  
H. Mantoan ◽  
C. Faloppa ◽  
...  
Keyword(s):  
Protein Expression ◽  
Uterine Leiomyosarcoma ◽  
Top2a Gene

scholarly journals Prognostic Significance of TOP2A Gene Dosage in HER‐2‐Negative Breast Cancer

2012 ◽  
Vol 17 (10) ◽  
pp. 1246-1255 ◽  
Author(s):  
Anna J. Żaczek ◽  
Aleksandra Markiewicz ◽  
Barbara Seroczyńska ◽  
Jarosław Skokowski ◽  
Janusz Jaśkiewicz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Dosage ◽  
Prognostic Significance ◽  
Top2a Gene ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document